DCM
TVTX icon

Delpha Capital Management’s Travere Therapeutics TVTX Stock Holding History

Delpha Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-821
Closed -$17K – 1146
2017
Q4 		$17K Buy
+821
New +$18.8K 0.02% 858

Other funds holding TVTX

SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Delpha Capital Management's TVTX Position: Q1 2018 in Review

Delpha Capital Management sold out of Travere Therapeutics (TVTX) in Q1 2018, closing a stake of 821 shares — an estimated $17K sold.

Delpha Capital Management first reported a position in TVTX in Q4 2017 and held it in 1 quarter. The position peaked at $17K in Q4 2017. 119 funds tracked by Wall St. Rank hold TVTX as of Q1 2018.

  • Delpha Capital Management reported no remaining Travere Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 821 Travere Therapeutics shares in Q1 2018, an estimated $17K.
  • Delpha Capital Management first reported a position in Travere Therapeutics in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Travere Therapeutics position peaked at $17K in Q4 2017.
  • 119 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.